Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Schizophr Res. 2015 Jun 20;166(0):219–224. doi: 10.1016/j.schres.2015.06.002

Figure 3.

Figure 3

Expression of B3GNT8 and MGAT4A in frontal cortex from male rats treated for nine months with haloperidol decanoate or vehicle. Data are presented as the ratio of signal intensity of each target protein to intensity of valosin-containing protein (VCP) labeling from the same lane of the same blot. Bars represent means ± standard deviation. Chronic haloperidol treatment did not change expression of either B3GNT8 or MGAT4A.